STANFORD, California, December 2, 2025: Researchers at Stanford Medicine have reported a significant advance in the treatment of Type 1 diabetes, demonstrating a complete reversal of the disease in laboratory mice through an immune system reset and transplantation of donor cells. The findings, announced by Stanford University School of Medicine in late November, describe how scientists successfully combined two established medical procedures blood-forming stem cell transplantation and pancreatic islet cell transplantation to restore normal insulin production in diabetic mice.
Stanford scientists report diabetes reversal in mice using donor stem and islet cells. (AI-generated Image)
The approach effectively stopped the animals’ immune systems from attacking the insulin-producing cells that are normally destroyed in Type 1 diabetes. In the study, mice received transplants from immunologically mismatched donors. The procedure replaced their insulin-producing beta cells while rebuilding their immune systems using donor blood stem cells. Following the treatment, the mice maintained stable blood glucose levels without insulin injections or immune-suppressing medication for the six-month duration of observation. None of the animals developed graft-versus-host disease, a serious condition often seen in mismatched transplants.
According to Stanford Medicine, all 19 pre-diabetic mice in the study remained disease-free, while an additional nine mice with established Type 1 diabetes achieved full remission. Researchers described the outcome as evidence that the dual transplant approach can induce immune tolerance to donor islet cells, eliminating the autoimmune reaction that causes the disease. The procedure used a conditioning protocol considered far milder than conventional bone marrow transplants. It involved low-dose radiation, immune-targeting antibodies, and a medication already approved for autoimmune conditions.
Scientists report complete diabetes remission in all test mice
This gentler preparation allowed donor stem cells to engraft effectively and create a hybrid immune system composed of both donor and recipient cells, while reducing risks associated with more intensive treatments. Dr. Seung K. Kim, who led the research at Stanford, said the experiment offers new insight into how immune and regenerative therapies might be combined to address autoimmune disorders. The study also demonstrated that donor islet cells can survive and function long-term once the immune system is rebalanced.
The team noted that several elements of the treatment including stem cell transplantation and immune modulation are already used clinically for other conditions. This overlap could make it easier to adapt the approach for further safety and efficacy testing. However, the researchers emphasized that the results are currently limited to animal models and were achieved under controlled laboratory conditions. The discovery builds on years of research into immune tolerance and regenerative cell therapies aimed at replacing or protecting insulin-producing cells.
Stanford results highlight potential for cell-based therapies
It represents a potential shift in how autoimmune diseases are approached, focusing on immune reeducation rather than suppression. Stanford Medicine’s announcement has drawn wide attention within the biomedical community for its clear demonstration that Type 1 diabetes can be reversed in an animal model by correcting the immune system malfunction at its source. The study underscores growing progress in cell-based and immune-targeted therapies that aim to restore natural insulin production and reduce dependence on lifelong insulin therapy.
If future studies confirm similar results in humans, the approach could help develop long-term immune tolerance for people with Type 1 diabetes, potentially allowing transplanted insulin-producing cells to function without the need for lifelong immunosuppressive drugs. Researchers at Stanford said additional preclinical work and safety evaluations are required before the method can advance to early-stage human trials, which remain several years away. – By Content Syndication Services.